Caffeine

Individuals with uncontrolled hypertension should monitor caffeine intake due to acute blood pressure elevation.

Patients with pre-existing arrhythmias or long QT syndrome should limit caffeine intake. Risk is primarily at high doses (>500 mg) or with concentrated products.

Caffeine reliably provokes panic attacks in patients with panic disorder. Meta-analysis by Klevebrant & Frick (2022) confirms this across multiple controlled studies. Avoidance or strict minimization is recommended.

Caffeine exacerbates anxiety symptoms dose-dependently. Individuals with anxiety disorders should limit intake to <200 mg/day or avoid entirely depending on individual sensitivity.

fluvoxamine use, ciprofloxacin use, enoxacin use

Patients on fluvoxamine, ciprofloxacin, or enoxacin face dramatically elevated caffeine exposure and should reduce intake proportionally.

Greenwood et al. (2014) meta-analysis: per 100mg increment, +14% spontaneous abortion risk, +19% stillbirth, +7% low birth weight. EFSA/WHO recommend ≤200 mg/day.

Neonatal CYP1A2 immaturity results in dramatically prolonged half-life. Caffeine administration in neonates is therapeutic only and requires supervised medical dosing.